0 followers
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being eva... Read more
Andrew Cheng
Kyverna Therapeutics
5 followers
Forge Biologics
2 followers
Vaxcyte
2 followers
Verve Therapeutics
54 followers
Ventyx Biosciences
1 follower
Edgewise Therapeutics
1 follower
nSide
3 followers
iECURE
1 follower
Generate Biomedicines
3 followers
Cellares
2 followers
Thermo Fisher Scientific
149 followers
Discover companies